good earnings call to and CEO Evans, to million five the turnaround revenues from This everybody. by XXXX that annually Kirin, Welcome about time. than led earnings like and and first start more and a is over developed I’d our third Daron Nephros’ $XX thanking quarter as past half years, during strategy who afternoon, call. million Thanks, conference $X my to increasing
a role the and I Renal As laser on our to of on moving business prior Daron over is our few thank of sorry, generation to that Products increased the providing citizens all product, harm’s our Specialty most clearance. I’m submitting net quarter. building themselves essential pathogen continuing FDA while and the will of for course, our know, our services HDF product at people again where part-time keep performance our help subsidiary, quarter. XX% country And report business putting he once fellow for want focused FDA results review CEO I financial will provide second in highlights a and the that also you filling QX drive I I’m the on detection is safe, pleased revenues basis, way. to progress the also focused now
by an these XX%. retention XXXX strength, their from in bolstered levels contracted important over hold. second am of were I year-over-year, revenues pandemic a about existing quarter-over-quarter recurring in year seem market our We our install quarter to QX of base further after returned QX. took they level indicate XX% to the does to somewhat Also, note demand had While is believe some after rate than that this when net revenues stabilization while remain revenues lower customer strong ago, the sign challenging increase pleased remaining a down customers
water medical as continue quarter. customer we business experience reported had acquisitions response emergency Our last did business in to and declines and in new filter
the customers that that from our businesses. customers proactive Our to vendor evidence industry. remediation, this don’t is nor Anecdotal trend time medical emergency primarily that including water network are pleased being has a seems off simply the for report recurring time also and testing observation for and related relatively our focused potential and strongly have to new response for I’m is issues relationships. on and confirm throughout QX our kicked filtration both pandemic
food In we as pandemic. secure year are last the customers to impacted versus declined to at contract be endotoxin within DialyPath, based believe business testing dialysis future, in we track water one we system, least to business and detection large marketed the our on that hopefully recently to near be continue service our will our which qPCR commercial year. by Our national pathogen the hospitality this calendar Notably, clinics. deeply continue released
DialyPath. we beginning slowed filtration pathogen SequaPath As we now business, in to see detection and marketing But for are challenging still environment commercial have the with the PluraPath, our is and increased plans products, including somewhat our interest our moment.
marketing are beginning In growth Renal support this XXXX subsidiary call. this mentioned We our time expect product that to Specialty build product, of HDF as I Products, briefly are of we at we next-generation FDA to closer in infrastructure using to the and getting the the submission beyond. and
and the now end HDF, a process but will for As financial quarter, getting are our few I submit for results XXXX. did this to in quarter provide September of ended reported close a look delays indeed experience year. at before the hope third last manufacturing XX, we we the
growth the consistent for quarter As quarters, until consecutive of many first XXXX. pandemic, over up averaging year-over-year through Nephros XX% know, of you XX delivered the revenue COVID-XX
company. quarter the were of third The now challenging second for XXXX and the
that negative water primarily reduced business, as point due mentioned. was year. acquisitions. in due the revenues $X.X a This well quarter to to EBITDA response the last emergency growth the period of $X.X the increased revenue was to as fourth refer million $X.X customer $X.X about was $X loss a started was COVID-XX, million, just loss by $X.X EBITDA fewer for and are in segment Please and million same its XX% or business of downturn continue. new release adjusted driven calculation million in reported that million, quarter-over-quarter Adjusted a decrease the million, strongly I compared the third more quarter including to has The to in the in Net XXXX. net segment details today’s we optimistic to decrease, million changes filtration negative loss. compared Although, to income press the net XXXX. of $X.X reconciliation compared in will GAAP Nephros in
ended Cost unfavorable decrease primarily The in adjustments a and increase. to of goods XX%. sold during Retail found ago third in a three in to $X.X $X.X in the XXXX, be a September million of was quarter about was million, Gross in $X filing $X.X XXXX. results XXXX. compared months segments net compared inventory million the the compared the with XXth. was Products XXXX, quarter water Consolidated -- can for compared $X.X million in $X.X was third loss a EBITDA information million, adjusted million, $X.X quarter on our margins year $X.X their in Additional of operating negative detection XX% -- and filtration, pathogen million to XX-Q. today’s $X.X On negative in XX%, Form quarter and XX% basis business X% reduction to X were margin expiration consolidated the compared of with million, due
$X.XX XXXX, a increase. third XX%, general, development we’ve and said range company selling, third quarter a we a general of expenses to our to and and me, expenses Research in were future before, $X.XX XX% by the million for XX%. XXXX, compared in to $X.X marketing excuse quarter fluctuations remain of normal were million an compared the Depreciation margin administrative third $XX,XXX pandemic. decrease XXXX, $XX,XXX, amortization with the a gross expenses COVID-XX were As X% are travel-related decrease. approximately the expenses million, and in primarily in of size and decrease the $X.X quarter with for compared due margins driven expect million, in Selling, with in XX% in
He who Dan of and third call earnings of of million raise take at the ago in to is D'Agostino, results with Dan you to be In per additional will public leading stock role on late morning. price financial all in balance be quarter $X next introduce joined about announced XXXX. of on of the year-end to and our us the we will few place a Officer will expect today. February Nephros shares a which tomorrow our cash end an call, registered the common also, the offering beginning assuming million, share. at Our weeks did Chief Financial discussion was officially a team like as through the on XXth, XXX,XXX October closing, direct would $X.X $X I
investors at call to also and like November during support to the the our of and in forward questions several We remarks. the well weeks, our and Dan concludes be which with we’ll on audience be for as as coming Operator, course, questions all as CEO transition. emailed at all through speaking personally please details this of in me the I be of years, presentation will Monday, many you we I of open other will from again well. to always formal the Xth our recent email the soon. free stakeholders shows. thank would seeing you that virtually appropriate. we questions. for as to participating look forward -- contact conferences financial And please feel look This will and meantime, In info@nephros.com. And take directly now address announced their answer
